FDA Prescription Drug User Fee Program Will Get OIG Appraisal
This article was originally published in The Pink Sheet Daily
Executive Summary
In addition to user fees, upcoming FDA reviews will also focus on oversight of post-marketing requirements and information exchange in the drug supply chain.